# MiR-27a-3p promotes the osteogenic differentiation by activating CRY2/ERK1/2 axis

**Authors:** Li-Rong Ren, Ru-Bin Yao, Shi-Yong Wang, Xiang-Dong Gong, Ji-Tao Xu, Kai-Shun Yang

PMC · DOI: 10.1186/s10020-021-00303-5 · Molecular Medicine · 2021-04-26

## TL;DR

This study shows that miR-27a-3p helps bone formation by targeting CRY2 and activating ERK1/2, offering a potential new treatment for osteoporosis.

## Contribution

The paper identifies the miR-27a-3p/CRY2/ERK1/2 axis as a novel mechanism in osteogenic differentiation.

## Key findings

- miR-27a-3p increases ERK1/2 phosphorylation and reduces CRY2 expression during osteogenic differentiation.
- Downregulating miR-27a-3p or overexpressing CRY2 reverses osteogenic effects in MC3T3-E1 cells.
- miR-27a-3p inhibits apoptosis in osteoblasts and directly targets CRY2.

## Abstract

Osteoporosis seriously disturbs the life of people. Meanwhile, inhibition or weakening of osteogenic differentiation is one of the important factors in the pathogenesis of osteoporosis. It was reported that miR-27a-3p reduced the symptoms of osteoporosis. However, the mechanism by which miR-27a-3p in osteogenic differentiation remains largely unknown.

To induce the osteogenic differentiation in MC3T3-E1 cells, cells were treated with osteogenic induction medium (OIM). RT-qPCR was used to evaluate the mRNA expression of miR-27a-3p and CRY2 in cells. The protein levels of CRY2, Runt-related transcription factor 2 (Runx2), osteopontin (OPN), osteocalcin (OCN) and the phosphorylation level of extracellular regulated protein kinases (ERK) 1/2 in MC3T3-E1 cells were evaluated by western blotting. Meanwhile, calcium nodules and ALP activity were tested by alizarin red staining and ALP kit, respectively. Luciferase reporter gene assay was used to analyze the correlation between CRY2 and miR-27a-3p.

The expression of miR-27a-3p and the phosphorylation level of ERK1/2 were increased by OIM in MC3T3-E1 cells, while CRY2 expression was decreased. In addition, OIM-induced increase of calcified nodules, ALP content and osteogenesis-related protein expression was significantly reversed by downregulation of miR-27a-3p and overexpression of CRY2. In addition, miR-27a-3p directly targeted CRY2 and negatively regulated CRY2. Meanwhile, the inhibitory effect of miR-27a-3p inhibitor on osteogenic differentiation was reversed by knockdown of CRY2 or using honokiol (ERK1/2 signal activator). Furthermore, miR-27a-3p significantly inhibited the apoptosis of MC3T3-E1 cells treated by OIM. Taken together, miR-27a-3p/CRY2/ERK axis plays an important role in osteoblast differentiation.

MiR-27a-3p promoted osteoblast differentiation via mediation of CRY2/ERK1/2 axis. Thereby, miR-27a-3p might serve as a new target for the treatment of osteoporosis.

## Linked entities

- **Genes:** CRY2 (cryptochrome circadian regulator 2) [NCBI Gene 1408], RUNX2 (RUNX family transcription factor 2) [NCBI Gene 860], SPP1 (secreted phosphoprotein 1) [NCBI Gene 6696], BGLAP (bone gamma-carboxyglutamate protein) [NCBI Gene 632], erk1/2 (mitogen-activated protein kinase) [NCBI Gene 778596]
- **Proteins:** CRY2 (cryptochrome circadian regulator 2), RUNX2 (RUNX family transcription factor 2), bglap2 (bone gamma-carboxyglutamate (gla) protein (osteocalcin) 2), erk1/2 (mitogen-activated protein kinase)
- **Chemicals:** honokiol (PubChem CID 72303)
- **Diseases:** osteoporosis (MONDO:0005298)

## Full-text entities

- **Genes:** Casp3 (caspase 3) [NCBI Gene 12367] {aka A830040C14Rik, AC-3, CASP-3, CC3, CPP-32, CPP32}, Gapdh (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 14433] {aka Gapd}, Mir223 (microRNA 223) [NCBI Gene 723814] {aka Mirn223, miR-223, mmu-mir-223}, Akt1 (Akt serine/threonine kinase 1) [NCBI Gene 11651] {aka Akt, LTR-akt, PKB, PKB/Akt, PKBalpha, Rac}, ERK1/2 [NCBI Gene 26417;26413], Map1lc3a (microtubule-associated protein 1 light chain 3 alpha) [NCBI Gene 66734] {aka 1010001H21Rik, 4922501H04Rik, LC3, LC3a}, Runx2 (runt related transcription factor 2) [NCBI Gene 12393] {aka AML3, CBF-alpha-1, Cbf, Cbfa-1, Cbfa1, LS3}, Spry4 (sprouty RTK signaling antagonist 4) [NCBI Gene 24066] {aka A030006O18Rik, sprouty4}, Cry2 (cryptochrome circadian regulator 2) [NCBI Gene 12953] {aka D130054K12Rik}, Clock (clock circadian regulator) [NCBI Gene 12753] {aka 5330400M04Rik, KAT13D}, Bax (BCL2-associated X protein) [NCBI Gene 12028], Pparg (peroxisome proliferator activated receptor gamma) [NCBI Gene 19016] {aka Nr1c3, PPAR-gamma, PPAR-gamma2, PPARgamma, PPARgamma2}, Grem1 (gremlin 1, DAN family BMP antagonist) [NCBI Gene 23892] {aka Cktsf1b1, Drm, Grem, ld}, Bmal1 (basic helix-loop-helix ARNT like 1) [NCBI Gene 11865] {aka Arnt3, Arntl, BMAL1b, MOP3, bHLHe5, bmal1b'}, Mir27a (microRNA 27a) [NCBI Gene 387220] {aka Mirn27a, mir-27a, mmu-mir-27a}, Mapk1 (mitogen-activated protein kinase 1) [NCBI Gene 26413] {aka 9030612K14Rik, ERK, Erk2, MAPK2, PRKM2, Prkm1}, CRY2 (cryptochrome circadian regulator 2) [NCBI Gene 1408] {aka HCRY2, PHLL2}, CRY1 (cryptochrome circadian regulator 1) [NCBI Gene 1407] {aka DSPD, PHLL1}, alp (alopecia, recessive) [NCBI Gene 11691], Cry1 (cryptochrome circadian regulator 1) [NCBI Gene 12952] {aka Phll1}, Ep300 (E1A binding protein p300) [NCBI Gene 328572] {aka A430090G16, A730011L11, KAT3B, p300, p300 HAT}, Fto (FTO alpha-ketoglutarate dependent dioxygenase) [NCBI Gene 26383] {aka mKIAA1752}, Bmal2 (basic helix-loop-helix ARNT like 2) [NCBI Gene 272322] {aka 4632430A05Rik, Arntl2, CLIF, MOP9, bHLHe6}, Spp1 (secreted phosphoprotein 1) [NCBI Gene 20750] {aka 2AR, Apl-1, BNSP, BSPI, Bsp, ETA-1}, Bcl2 (B cell leukemia/lymphoma 2) [NCBI Gene 12043] {aka Bcl-2, C430015F12Rik, D630044D05Rik, D830018M01Rik}, Mapk3 (mitogen-activated protein kinase 3) [NCBI Gene 26417] {aka Erk-1, Erk1, Ert2, Esrk1, Mnk1, Mtap2k}, Bglap2 (bone gamma-carboxyglutamate protein 2) [NCBI Gene 12097] {aka BGP2, Bglap1, Bgp, Og2, mOC-B}, PER2 (period circadian regulator 2) [NCBI Gene 8864] {aka FASPS, FASPS1}, PER3 (period circadian regulator 3) [NCBI Gene 8863] {aka FASPS3, GIG13}, Slit2 (slit guidance ligand 2) [NCBI Gene 20563] {aka Drad-1, E030015M03Rik, E130320P19Rik, Slil3, b2b1200.1Clo, mKIAA4141}
- **Diseases:** bone disease (MESH:D001847), cancer (MESH:D009369), ODM (MESH:D012516), Osteoporosis (MESH:D010024), fractures (MESH:D050723)
- **Chemicals:** polyphenol (MESH:D059808), 2-(4-hydroxy-3-prop-2-enyl-phenyl)-4-prop-2-enylphenol (-), water (MESH:D014867), Alizarin Red (MESH:C010078), beta-glycerophosphate (MESH:C031463), PBS (MESH:D007854), astragalin (MESH:C001579), DMSO (MESH:D004121), Alizarin Red S (MESH:C004468), Oligonucleotides (MESH:D009841), propidium iodide (MESH:D011419), SDS (MESH:D012967), Honokiol (MESH:C005499), dexamethasone (MESH:D003907), polyvinylidene fluoride (MESH:C024865), Tween 20 (MESH:D011136), Lipofectamine 2000 (MESH:C086724), L-ascorbic acid (MESH:D001205), ethanol (MESH:D000431), SYBR Green I (MESH:C098022), calcium (MESH:D002118), LPS (MESH:D008070), puerarin (MESH:C033607),  (MESH:D056931),  (MESH:C538967)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** MUT — Homo sapiens (Human), Amyotrophic lateral sclerosis 14, with or without frontotemporal dementia, Induced pluripotent stem cell (CVCL_VF13), MC3T3-E1 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0409), MC3T3 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0D74), MG-63 — Homo sapiens (Human), Osteosarcoma, Cancer cell line (CVCL_0426)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC8077963/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC8077963/full.md

## References

45 references — full list in the complete paper: https://tomesphere.com/paper/PMC8077963/full.md

---
Source: https://tomesphere.com/paper/PMC8077963